🌍·7h agoIndustry
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
Publisher
T
Tiziana Life Sciences
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Tiziana Life Sciences
- Region
- 最新
- Scope
- Industry
- Published
- September 21, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on tizianalifesciences.com
Leave the platform to read the original full article on the publisher site.
Source: Tiziana Life Sciences
Scope: Industry
Related coverage
More related coverage
Roche Newsroom/2h ago
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
AbbVie News/6h ago
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Merck & Co. (MSD) News/7h ago
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
University of Minnesota/1h ago